Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
Rangering i aksjer #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
Aksjekurs
$1.51
Sist synkronisert: 2024-08-26
Markedsverdi
$1.12M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Agile Therapeutics, Inc. (AGRX)

Kategori

Inntekter for Agile Therapeutics, Inc. (AGRX)
Inntekter i Jun 2024 TTM: $21.57M
Ifølge de nyeste økonomiske rapportene til Agile Therapeutics, Inc. er selskapets nåværende inntekter (TTM) $21.57M. I 2022 hadde selskapet inntekter på $10.88M en økning sammenlignet med inntektene i 2021, som var $4.10M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Agile Therapeutics, Inc. fra 2012 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $21.57M 10.08%
2023 $19.59M 80.02%
2022 $10.88M 165.40%
2021 $4.10M 447.53%
2020 $749.00K 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Inntekter for lignende selskaper eller konkurrenter